Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).
*The following content is generated by AI and is for reference only.
Aprocitentan is a novel, orally active, non-peptide endothelin receptor antagonist (ERA) currently under development for the treatment of hypertension and chronic kidney disease. It functions by selectively blocking both endothelin type A (ETA) and type B (ETB) receptors. Endothelin-1 is a potent vasoconstrictor peptide that plays a central role in regulating blood pressure and vascular tone; by inhibiting its interaction with these receptors, Aprocitentan promotes vasodilation and reduces systemic vascular resistance. This dual antagonism distinguishes it from earlier ERA agents like bosentan or ambrisentan, which often exhibit selectivity for only one receptor subtype, potentially offering a more balanced physiological effect.
The molecular formula of Aprocitentan is C24H29N3O5S, and its CAS registry number is 1896076-93-3. These chemical identifiers are crucial for pharmaceutical manufacturing, regulatory compliance, and research documentation. The drug has garnered significant attention in clinical trials due to its potential efficacy in lowering blood pressure without the dose-limiting fluid retention issues commonly associated with other ERAs. Furthermore, preclinical and early clinical data suggest renoprotective properties, making it a promising candidate for patients with hypertensive chronic kidney disease who require aggressive blood pressure control to slow renal decline.
Unlike traditional diuretics or ACE inhibitors, Aprocitentan offers a unique mechanism of action targeting the endothelin system, which may benefit patients resistant to standard therapies. Its oral bioavailability allows for convenient once-daily dosing, improving patient adherence compared to injectable alternatives. While long-term safety profiles are still being established through Phase III clinical studies, the initial results indicate a favorable therapeutic window. As the global burden of cardiovascular and renal diseases continues to rise, Aprocitentan represents a significant advancement in precision medicine, aiming to provide a targeted solution for complex hypertension management. Ongoing research focuses on optimizing dosing strategies and expanding indications to include heart failure and pulmonary arterial hypertension, solidifying its position as a next-generation therapeutic agent in the cardiovascular pharmacopeia.